These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 11797703)

  • 21. Food and Drug Administration regulation of tobacco products: introduction.
    Shatenstein S
    Tob Control; 2004 Dec; 13(4):438. PubMed ID: 15564632
    [No Abstract]   [Full Text] [Related]  

  • 22. The Food and Drug Administration's regulation of risk disclosure for implantable cardioverter defibrillators: has technology outpaced the Agency's regulatory framework?
    Basile EM; Lorell BH
    Food Drug Law J; 2006; 61(2):251-72. PubMed ID: 16903031
    [No Abstract]   [Full Text] [Related]  

  • 23. Partnership insurance. An innovation to meet LTC financing needs.
    Meiners MR
    Caring; 2001 Apr; 20(4):26-7. PubMed ID: 11301967
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is FDA's medical device evaluation process overly complaisant to industry?
    Margolis RE
    Healthspan; 1992; 9(7):19-20. PubMed ID: 10121440
    [No Abstract]   [Full Text] [Related]  

  • 25. The Biomarkers Consortium: public and private sectors working in partnership to improve the public health.
    Zerhouni EA; Sanders CA; von Eschenbach AC
    Oncologist; 2007 Mar; 12(3):250-2. PubMed ID: 17405889
    [No Abstract]   [Full Text] [Related]  

  • 26. Must an interest be a conflict?
    Lyles A
    Clin Ther; 2005 Mar; 27(3):344-5. PubMed ID: 15878388
    [No Abstract]   [Full Text] [Related]  

  • 27. A pivotal medical-device case.
    Curfman GD; Morrissey S; Drazen JM
    N Engl J Med; 2008 Jan; 358(1):76-7. PubMed ID: 18172178
    [No Abstract]   [Full Text] [Related]  

  • 28. FDA set to tighten guidelines on industry dissemination of information on unapproved uses of medical products.
    Lang L
    Gastroenterology; 2008 Apr; 134(4):905. PubMed ID: 18395067
    [No Abstract]   [Full Text] [Related]  

  • 29. Understanding physician responsibilities and limitations for drug and device off-label use.
    Sclafani AP
    Facial Plast Surg Clin North Am; 2007 May; 15(2):251-4, viii. PubMed ID: 17544942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Control of tuberculosis in an urban setting in Nepal: public-private partnership.
    Newell JN; Pande SB; Baral SC; Bam DS; Malla P
    Bull World Health Organ; 2004 Feb; 82(2):92-8. PubMed ID: 15042230
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Refining the concept of public/private partnerships.
    Egnew RC
    Behav Healthc Tomorrow; 1996 Apr; 5(2):37-9. PubMed ID: 10157575
    [No Abstract]   [Full Text] [Related]  

  • 32. Microarray data--the US FDA, industry and academia.
    Hackett JL; Lesko LJ
    Nat Biotechnol; 2003 Jul; 21(7):742-3. PubMed ID: 12833089
    [No Abstract]   [Full Text] [Related]  

  • 33. Global health. Public-private partnerships proliferate.
    Cohen J
    Science; 2006 Jan; 311(5758):167. PubMed ID: 16410497
    [No Abstract]   [Full Text] [Related]  

  • 34. Watching over the medical device industry.
    Lenzer J
    BMJ; 2009 Jun; 338():b2321. PubMed ID: 19549649
    [No Abstract]   [Full Text] [Related]  

  • 35. Devices and the food and drug administration.
    Phillips SJ; Phillips RS
    Artif Organs; 2005 May; 29(5):363-5. PubMed ID: 15854210
    [No Abstract]   [Full Text] [Related]  

  • 36. User fees and medical device reviews.
    Lewis C
    FDA Consum; 2003; 37(2):18-9. PubMed ID: 12715765
    [No Abstract]   [Full Text] [Related]  

  • 37. Working together to enhance the efficiency of medical product development.
    Sanhai WR
    J Nucl Med; 2008 Jun; 49(6):43N-45N. PubMed ID: 18511823
    [No Abstract]   [Full Text] [Related]  

  • 38. PMA primacy: synthesizing the 35 U.S.C. Section 156 patent term extension, 35 U.S.C. Section 271(e)(1) patent infringement exemption as currently applied to medical devices, and medical device preemption jurisprudence to yield a cohesive solution regarding scope of coverage.
    Flaherty JM
    Food Drug Law J; 2001; 56(3):339-49. PubMed ID: 11944643
    [No Abstract]   [Full Text] [Related]  

  • 39. Public-private partnerships for hospitals.
    McKee M; Edwards N; Atun R
    Bull World Health Organ; 2006 Nov; 84(11):890-6. PubMed ID: 17143463
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clarification: 510k is premarket notification; it provides no patent or FDA approval.
    Burkhart CG
    J Drugs Dermatol; 2008 Feb; 7(2):105. PubMed ID: 18335644
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.